# Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

> **NCT06620822** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 296 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** IBI363
- **DRUG:** LM-108+Sintilimab
- **DRUG:** IBI310+Sintilimab
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06620822
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 296 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06620822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06620822, "Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06620822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*